Murphy Canyon Acquisition Corp. Warrant

Murphy Canyon Acquisition Corp. Warrant is a publicly traded derivative security that provides the holder the right, but not the obligation, to purchase shares of Conduit Pharmaceuticals Inc. common stock at a specified price. Originating from Murphy Canyon Acquisition Corp., a special purpose acquisition company (SPAC) formed to facilitate mergers and acquisitions, these warrants became associated with Conduit Pharmaceuticals following the completion of a business combination in September 2023. Each warrant entitles the holder to purchase one share of common stock at an exercise price of $11.50, becoming exercisable 30 days after the business combination and expiring five years after the closing date. These warrants play a specialized role in the capital markets by offering investors a leveraged exposure to the underlying equity of a multi-asset, disease-agnostic life sciences company focused on clinical-stage therapeutic development. The Murphy Canyon Acquisition Corp. Warrant supports capital formation for Conduit Pharmaceuticals while providing liquidity and flexibility for market participants interested in the company’s growth and innovation within the pharmaceutical sector.